Media coverage about Enanta Pharmaceuticals (NASDAQ:ENTA) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.7191962163847 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
A number of research analysts recently commented on the stock. Royal Bank of Canada downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a research report on Tuesday, January 2nd. JPMorgan Chase & Co. downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 8th. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 10th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 target price on the stock in a research report on Monday, February 12th. Finally, ValuEngine raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of “Buy” and an average target price of $57.40.
Enanta Pharmaceuticals (ENTA) opened at $81.10 on Wednesday. Enanta Pharmaceuticals has a 52-week low of $28.09 and a 52-week high of $95.91. The stock has a market cap of $1,550.00, a price-to-earnings ratio of 44.08 and a beta of 1.10.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).